Edward Chang1, Sarah Holt1, Bruce Montgomery2, Jonathan Wright1,3. 1. Department of Urology, University of Washington School of Medicine, Seattle, Washington. 2. Division of Medical Oncology, University of Washington School of Medicine, Seattle, Washington. 3. Division of Public Health Sciences, Fred Hutchinson Center Research Center, Seattle, Washington.
Abstract
Introduction: Although studies using mixed insurance populations suggest that chemotherapy use in men with advanced penile cancer (PC) is low, it is unclear what regimens are being utilized. In this study, we use a database of insured patients to better understand specific chemotherapy utilization in men with PC. Methods: This is a retrospective cohort study of patients with stage IIIB or IV PC in the Surveillance, Epidemiology, and End Results-Medicare database (2004-2015). Standard of care (SOC) chemotherapy was defined by the National Comprehensive Cancer Network® guidelines: 4 cycles of paclitaxel, ifosfamide and cisplatin or 5-fluorouracil with cisplatin in the neoadjuvant, adjuvant or primary setting. We calculated what proportion of patients receive SOC or any chemotherapy within 2 years of diagnosis and analyzed what factors were associated with receiving chemotherapy. Results: Our study included 147 patients-48 stage IIIB and 99 stage IV. Of these patients, 49 (33%) received chemotherapy. Less than 5% of men received SOC. About 10% received SOC chemotherapy but an insufficient number of cycles. Married men were more likely to undergo chemotherapy (OR 3.4, 95% CI 1.5-7.8). Less than 5% of the 24 Black or Hispanic patients received chemotherapy compared to 37% of white patients (p <0.001). Conclusions: Only a third of men with stage IIIB/IV PC underwent chemotherapy. Less than 5% of men received complete guideline-based regimens. Whether this is driven primarily by patient or provider factors is unknown, although social determinants of health may play a role. These data highlight the difficulty for patients with PC to get chemotherapy.
Introduction: Although studies using mixed insurance populations suggest that chemotherapy use in men with advanced penile cancer (PC) is low, it is unclear what regimens are being utilized. In this study, we use a database of insured patients to better understand specific chemotherapy utilization in men with PC. Methods: This is a retrospective cohort study of patients with stage IIIB or IV PC in the Surveillance, Epidemiology, and End Results-Medicare database (2004-2015). Standard of care (SOC) chemotherapy was defined by the National Comprehensive Cancer Network® guidelines: 4 cycles of paclitaxel, ifosfamide and cisplatin or 5-fluorouracil with cisplatin in the neoadjuvant, adjuvant or primary setting. We calculated what proportion of patients receive SOC or any chemotherapy within 2 years of diagnosis and analyzed what factors were associated with receiving chemotherapy. Results: Our study included 147 patients-48 stage IIIB and 99 stage IV. Of these patients, 49 (33%) received chemotherapy. Less than 5% of men received SOC. About 10% received SOC chemotherapy but an insufficient number of cycles. Married men were more likely to undergo chemotherapy (OR 3.4, 95% CI 1.5-7.8). Less than 5% of the 24 Black or Hispanic patients received chemotherapy compared to 37% of white patients (p <0.001). Conclusions: Only a third of men with stage IIIB/IV PC underwent chemotherapy. Less than 5% of men received complete guideline-based regimens. Whether this is driven primarily by patient or provider factors is unknown, although social determinants of health may play a role. These data highlight the difficulty for patients with PC to get chemotherapy.
Authors: Lance C Pagliaro; Dallas L Williams; Danai Daliani; Michael B Williams; William Osai; Michael Kincaid; Sijin Wen; Peter F Thall; Curtis A Pettaway Journal: J Clin Oncol Date: 2010-07-12 Impact factor: 44.544
Authors: Mounsif Azizi; Ahmet M Aydin; Ali Hajiran; Andrew Lai; Ambuj Kumar; Charles C Peyton; Suks Minhas; Guru P Sonpavde; Jad Chahoud; Lance C Pagliaro; Andrea Necchi; Philippe E Spiess Journal: J Urol Date: 2020-01-13 Impact factor: 7.450
Authors: Rebecca A Campbell; Emily A Slopnick; Elizabeth K Ferry; Hui Zhu; Simon P Kim; Robert Abouassaly Journal: Urol Oncol Date: 2017-03-28 Impact factor: 3.498
Authors: Shreyas S Joshi; Elizabeth Handorf; David Strauss; Andres F Correa; Alexander Kutikov; David Y T Chen; Rosalia Viterbo; Richard E Greenberg; Robert G Uzzo; Marc C Smaldone; Daniel M Geynisman Journal: JAMA Oncol Date: 2018-05-01 Impact factor: 31.777